期刊文献+

HPLC法测定头孢泊肟酯分散片中有关物质的含量 被引量:1

Content Determination of Related Substance in Cefpodoxime Proxetil Dispersible Tablet by HPLC
原文传递
导出
摘要 目的:建立测定头孢泊肟酯分散片中有关物质含量的方法。方法:采用高效液相色谱法。色谱柱为ODS(C18)柱,流动相为水-甲醇(55:45),流速为2.0mL·min-1,检测波长为240nm,柱温为25℃,进样量为20μL。结果:头孢泊肟酯A、头孢泊肟酯B与杂质能完全分离;头孢泊肟酯A最小检测限为1.6ng,头孢泊肟酯B最小检测限为1.2ng,其有关物质含量均<4.0%。结论:该方法简便、准确,灵敏度高,专属性强,可用于头孢泊肟酯分散片有关物质含量的测定。 OBJECTIVE: To establish the method for the content determination of the related substances in Cefpodoxime proxetil tablet. METHODS: HPLC method was adopted. The determination was performed on ODS (C18) column with water-methanol (55:45) as mobile phase at the flow rate of 2.0 mL.min^-1. The detection wavelength was set at 240 nm and column temperature was 25 ℃. Injection volume was 20 μL. RESULTS: Cefpodoxime proxetil A and cefpodoxime proxefil B could be separated from impurity completely. The lowest detectable limit of cefpodoxime proxetil A was 1.6 ng and that of cefpodoxime proxetil B was 1.2 ng. The contents of the related substances were less than 4.0%. CONCLUSION: The method is convenient, accurate, sensitive and specific. It is suitable for the content determination of the related substances in Cefpodoxime proxetil dispersible tablet.
作者 俞平
出处 《中国药房》 CAS CSCD 北大核心 2011年第40期3822-3823,共2页 China Pharmacy
关键词 头孢泊肟酯 分散片 有关物质 高效液相色谱法 Cefpodoxime proxetil Dispersible tablet Related substance HPLC
  • 相关文献

参考文献3

  • 1邵长周,瞿介明,何礼贤.第3代口服头孢菌素——头孢泊肟酯[J].中国新药与临床杂志,2004,23(11):746-750. 被引量:12
  • 2Yamasaki T,Moritake K,Akiyama Y,et al.Microvascular Doppler ultrasound-assisted neuroendoscopic surgery [J].Br J Neurosurg,2000,14 (5): 464-467.
  • 3Auer LM.Ultrasound stereotaxic endoscopy in neurosurgery[J].Acta Neurochir Suppl,1992,54: 34-41.

二级参考文献11

  • 1FRAMPTON JE, EBOGDEN RN, LANGTRY HD, et al. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential [J]. Drugs, 1992,44(5):889-917.
  • 2-[8]See above
  • 3FUNG-TOMC JC, HUCZKO E, STICKLE T, et al. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides [J]. Antimicrob Agents Chemother,1995,39(2):533-538.
  • 4FULTON B, PERRY CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients [J].Paediatr Drugs,2001,3(2):137-158.
  • 5CHOCAS EC, PAAP CM, GODLEY PJ. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin [J].Ann Pharmacother,1993,27(11):1369-1377.
  • 6SCHATZ BS, KARAVOKIROS KT, TAEUBEL MA, et al. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten [J]. Ann Pharmacother, 1996,30(3):258-268.
  • 7DESLANDES A, CAMUS F, LACROIX C, et al. Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration [J].Antimicrob Agents Chemother, 1996,40(12):2879-2881.
  • 8LUO SD, YU X, YIN WH, et al. Procession of Cefpodoxime proxetil in vivo [J]. Chin Pharm J (in Chinese),1996,31(2):110-112.
  • 9BERGOGNE-BEREZIN E. International clinical experience with cefpodoxime proxetil [J].Curr Ther Res,1996,57(Suppl A):103-115.
  • 10EDLUND C, STARK C, NORD CE. The relationship between an increase in β-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances [J].J Antimicrob Chemother,1994,34(1):127-138.

共引文献12

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部